September M&A deals picked up after a quiet summer with 23 M&A deals recorded, the busiest month of the year so far, which included two major deals closing at $4bn.
[Editors' note: For more details about M&A deals in 2016 and previous years, go to Medtech Insight's M&A deal tracker:https://medtech.pharmamedtechbi.com/datasets/mna]
September was the busiest month so far in 2016 for M&A deals with activity picking up following a summer slump. Medtech Insight’s M&A deal tracker recorded 23 transactions in total,...
The imaging, Varian, and advanced therapies segments – which are more reliant on equipment sales – are more heavily affected, with tariffs applying to roughly 55% of their revenue base. In diagnostics, the company expects minimal exposure due to sufficient US value-added manufacturing.
Cardiosense has launched a nationwide clinical study, SEISMIC-HF II, to validate its non-invasive, AI-powered technology for monitoring heart failure. The data will be used to file for US regulatory clearance of the Cardiosense heart failure monitoring platform.
Valued at over $1.9bn, ConcertAI is building on its pre-existing multi-agentic AI SaaS solution CARAai to bring life science customers the new Precision suite of applications: Precision Explorer, Precision Trials, Precision GTM and Precision360.
